Company Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function.
The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases.
Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases.
Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ms. Susan A. Knudson |
Contact Details
Address: 10655 Sorrento Valley Road, Suite 200 San Diego, California 92121 United States | |
| Phone | (858) 526-3100 |
| Website | histogen.com |
Stock Details
| Ticker Symbol | HSTO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001383701 |
| CUSIP Number | 43358Y103 |
| ISIN Number | US43358Y2028 |
| Employer ID | 20-3183915 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Susan A. Knudson | President, Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Chief Compliance Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 4, 2024 | 15-12G | Securities registration termination |
| Dec 15, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 14, 2023 | 425 | Filing |
| Dec 14, 2023 | 8-K | Current Report |
| Dec 5, 2023 | 425 | Filing |
| Dec 5, 2023 | 8-K | Current Report |
| Nov 16, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 16, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 16, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 16, 2023 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |